These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36124939)

  • 21. Intellectual property licensing of therapeutics during the COVID-19 crisis: lessons learnt for pandemic preparedness and response.
    Braimoh T; Burrone E; Gore C; Vijayaraghavan P
    Global Health; 2024 Jul; 20(1):52. PubMed ID: 38956614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Scaling Up the Global COVID-19 Vaccination Program: Production, Allocation, and Distribution with an Emphasis on Equity.
    Louden EM
    Yale J Biol Med; 2022 Sep; 95(3):379-387. PubMed ID: 36187418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inequitable COVID-19 vaccine distribution and the intellectual property rights prolong the pandemic.
    Altindis E
    Expert Rev Vaccines; 2022 Apr; 21(4):427-430. PubMed ID: 34878957
    [No Abstract]   [Full Text] [Related]  

  • 24. Intellectual property waiver for covid-19 vaccines will advance global health equity.
    Erfani P; Binagwaho A; Jalloh MJ; Yunus M; Farmer P; Kerry V
    BMJ; 2021 Aug; 374():n1837. PubMed ID: 34344728
    [No Abstract]   [Full Text] [Related]  

  • 25. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator.
    Saxena A; Baker BK; Banda A; Herlitz A; Miller J; Karrar K; Fleurbaey M; Chiwa E; Atuire CA; Hirose I; Hassoun N
    BMJ Glob Health; 2023 Jan; 8(1):. PubMed ID: 36650015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omicron is bad but the global response is worse.
    Nature; 2021 Dec; 600(7888):190. PubMed ID: 34876667
    [No Abstract]   [Full Text] [Related]  

  • 28. Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future.
    Pilkington V; Keestra SM; Hill A
    Front Public Health; 2022; 10():821117. PubMed ID: 35321196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.
    Kana BD; Arbuthnot P; Botwe BK; Choonara YE; Hassan F; Louzir H; Matsoso P; Moore PL; Muhairwe A; Naidoo K; Ndomondo-Sigonda M; Madhi SA
    Lancet Infect Dis; 2023 Aug; 23(8):e288-e300. PubMed ID: 37290473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Redressing COVID-19 vaccine inequity amidst booster doses: charting a bold path for global health solidarity, together.
    Rackimuthu S; Narain K; Lal A; Nawaz FA; Mohanan P; Essar MY; Charles Ashworth H
    Global Health; 2022 Feb; 18(1):23. PubMed ID: 35193616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What next for a COVID-19 intellectual property waiver?
    Zarocostas J
    Lancet; 2021 May; 397(10288):1871-1872. PubMed ID: 34022975
    [No Abstract]   [Full Text] [Related]  

  • 32. Access to COVID-19 Vaccines: A New Global Approach.
    Bouderhem R
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
    Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
    BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility.
    Eccleston-Turner M; Upton H
    Milbank Q; 2021 Jun; 99(2):426-449. PubMed ID: 33650737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the institutional landscape and proliferation of proposals for global vaccine equity for COVID-19: too many cooks or too many recipes?
    Geiger S; McMahon A
    J Med Ethics; 2023 Aug; 49(8):583-590. PubMed ID: 34848492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 - Inequities, the third wave and vaccination.
    Govender I
    S Afr Fam Pract (2004); 2021 Aug; 63(1):e1-e2. PubMed ID: 34476960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the proposed intellectual property waiver as a mechanism to address the COVID-19 vaccine scarcity problem.
    Barnes-Weise J; Santos Rutschman A; Adler R
    J Epidemiol Community Health; 2022 Apr; 76(4):317-318. PubMed ID: 35140119
    [No Abstract]   [Full Text] [Related]  

  • 38. Delayed Access to COVID-19 Vaccines: A Perspective on Low-income Countries in Africa.
    Hassan MA; Aliyu S
    Int J Health Serv; 2022 Jul; 52(3):323-329. PubMed ID: 35469499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Solidarity across borders: A pragmatic need for global COVID-19 vaccine equity.
    Obinna DN
    Int J Health Plann Manage; 2022 Jan; 37(1):21-29. PubMed ID: 34585430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.
    Mermelstein S; Stevens H
    Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.